---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-21-003222"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2021-08-02T23:59:59+00:00"
generated_at: "2026-06-29T23:47:44.804945+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte Biotech reports preliminary FY2021 net loss of $3.6M, cash $2.2M

## Summary
- Net loss for FY2021 was approx. $3.6M ($2.45 loss per share) vs. $3.8M ($4.23 loss per share) in FY2020.
- Cash on hand as of April 30, 2021 was approx. $2.2M.
- Results are preliminary and unaudited, subject to completion of financial closing procedures.

## SEC filing metadata
- accession: 0001683168-21-003222
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2021-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316821003222/0001683168-21-003222-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316821003222/pharma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-21-003222
- JSON: https://secwatch.observer/filing/0001683168-21-003222.json
- Plain text: https://secwatch.observer/filing/0001683168-21-003222.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.